Want to see HK:1302 full AI Analyst Report?
1302 Stock Chart & Stats
HK$1.58
HK$0.01(0.75%)
At close: 4:00 PM EST
HK$1.58
HK$0.01(0.75%)
Day’s Range― - ―
52-Week RangeHK$1.29 - HK$2.44
Previous CloseN/A
Volume6.38M
Average Volume (3M)16.26M
Market Cap
HK$5.92B
Enterprise ValueHK$4.58K
Total Cash (Recent Filing)HK$1.24B
Total Debt (Recent Filing)HK$14.10M
Price to Earnings (P/E)90.6
Beta0.90
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding4,631,712,400
10 Day Avg. Volume16,780,132
30 Day Avg. Volume16,261,953
Financial Highlights & Ratios
PEG Ratio-1.21
Price to Book (P/B)1.76
Price to Sales (P/S)4.52
P/FCF Ratio12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.47B
Bulls Say, Bears Say
Bulls Say
Revenue Growth Re-accelerationThe sharp 2025 revenue re-acceleration indicates stronger demand, product adoption, or geographic reach across the company’s cardiovascular and peripheral vascular device portfolio. If sustained, this growth can expand operating scale and support continued investment in medical-device innovation and commercialization.
Very Conservative Balance SheetExtremely low leverage materially reduces financial risk and interest-related pressure, giving LifeTech greater resilience through changes in procedure volumes or reimbursement. The sizable equity base also preserves flexibility to fund product development, regulatory expansion, and commercial growth without relying heavily on debt.
Improved Free-cash-flow QualityFree cash flow approaching reported net income is a constructive sign that earnings are producing usable internal funding. This supports investment in new devices and market expansion while reducing dependence on external capital, although the longer-term benefit depends on maintaining this conversion quality.
Bears Say
Sustained Margin CompressionThe multi-year decline in net margin shows that rapid revenue growth has not translated proportionately into bottom-line earnings. Persistent margin pressure could limit reinvestment capacity, weaken earnings quality, and make future profitability more dependent on delivering additional volume growth.
Declining Capital EfficiencyFalling ROE indicates that the company is generating less profit from its growing equity base, despite having minimal balance-sheet risk. Unless profitability improves, weaker capital efficiency may constrain sustainable earnings compounding and reduce the effectiveness of retained capital for future expansion.
Variable Cash ConversionAlthough 2025 free cash flow improved, the broader record shows uneven cash generation and only modest conversion of operating profit into operating cash. This variability can make internally funded investment less predictable and may reduce confidence that reported earnings consistently translate into liquidity.
LifeTech Scientific Corporation News
1302 FAQ
What was LifeTech Scientific Corporation’s price range in the past 12 months?
LifeTech Scientific Corporation lowest stock price was HK$1.28 and its highest was HK$2.44 in the past 12 months.
What is LifeTech Scientific Corporation’s market cap?
LifeTech Scientific Corporation’s market cap is HK$5.92B.
When is LifeTech Scientific Corporation’s upcoming earnings report date?
LifeTech Scientific Corporation’s upcoming earnings report date is Mar 31, 2027 which is in 195 days.
How were LifeTech Scientific Corporation’s earnings last quarter?
LifeTech Scientific Corporation released its earnings results on Aug 28, 2026. The company reported -HK$0.009 earnings per share for the quarter.
Is LifeTech Scientific Corporation overvalued?
According to Wall Street analysts LifeTech Scientific Corporation’s price is currently Overvalued.
Does LifeTech Scientific Corporation pay dividends?
LifeTech Scientific Corporation does not currently pay dividends.
What is LifeTech Scientific Corporation’s EPS estimate?
LifeTech Scientific Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LifeTech Scientific Corporation have?
LifeTech Scientific Corporation has 4,631,712,400 shares outstanding.
What happened to LifeTech Scientific Corporation’s price movement after its last earnings report?
LifeTech Scientific Corporation reported an EPS of -HK$0.009 in its last earnings report. Following the earnings report the stock price went down -0.36%.
Which hedge fund is a major shareholder of LifeTech Scientific Corporation?
Currently, no hedge funds are holding shares in HK:1302
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LifeTech Scientific Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. The company’s products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers. It also involved in the biomedical research and development; properties leasing business; and developing, manufacturing, and trading of medical devices, as well as offers technical, consulting, and technology services. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, China.
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―